A Randomized, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Xingnaojing for Acute Ischemic Stroke patients with Endovascular Thrombectomy

Beijing Tiantan Hospital, Capital Medical University0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Patients over 18 years old;
•2. Acute ischemic stroke was diagnosed
•3. MRA or CTA showed occlusion of anterior circulation arteries
•4. Acute intravascular therapy (including simple intravascular therapy and bridging therapy) within 24 hours of onset
•5. Randomization was completed within 24 hours after operation
•6. ICF should be signed by patients or family members

•1.Treated with Xingnaojing injection
•2. Patients with transient ischemic attack
•3. Patients with cerebral hemorrhage on imaging examination
•4. Patients with vasculitis
•5. ALTAST = 3 times of the upper limit of normal value, Cr = 2 times of the upper limit of normal value
•6. Patients with a tendency of bleeding, and severe bleeding occurred within 3 months
•7. Allergic to Xingnaojing, ethanol, glycerin or allergic constitution
•8. Patients with pregnancy planning, pregnancy or lactation
•9. Patients with severe heart, liver, kidney disease or malignant tumor, life expectancy < 3 months
•10. Patients participating in other drug clinical studies
•11. The patients who are not suitable for the clinical study (such as those with mental and mental disorders, etc.) are considered by the researchers.

发起方